Skip To Main Content
Zin W. Myint on Muck Rack

Zin W. Myint

As seen in: Nature, Frontiers, MDPI, JAMA (The Journal of the American Medical Association), Medical Xpress, UKNow, Oncology Nursing News
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zin W.

Contact Zin W., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)

|
By Patrizia Giannatempo, Shilpa Gupta, Mimma Rizzo, Karl J.J. Mayrhofer, Renate Pichler, Dora Niedersuess-Beke, Ondrej Fiala, Javier Molina-Cerrillo, Marc Matrana, Luca Galli, Tomas Buchler, Alina Pirshtuk, Jawaher Ansari, Anca Zgura, Ray Manneh Kopp, Giandomenico Roviello, Jindřich Kopecký, Akihiro Yano, Martin Angel, Ravindran Kanesvaran, Zin W. Myint, Yuksel Urun, Francesco Massari, Kannan Sridharan, Matteo Santoni, Randi Kinhel, Alessia Salfi, Kirstin Binz
| Nature Verified
Abstract Enfortumab vedotin (EV) is an antibody–drug conjugate targeting Nectin-4 and is approved for patients with advanced urothelial carcinoma (UC) who have progressed after platinum-based chemotherapy and immune checkpoint inhibitors. While clinical trials have demonstrated manageable safety profiles, real-world toxicity data remain limited.
Open in Who Shared Issue with article?

QOL, Pain Not Changed by 177Lu-PSMA-617 Triplet in mHSPC

|
By Ryan Scott Verified, Spencer Feldman Verified, Zin W. Myint
| Oncology Nursing News Verified
The combination of lutetium Lu 177 prostate-specific membrane antigen 617 (177Lu-PSMA-617; Pluvicto) with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) produced similar quality-of-life (QOL) outcomes vs ADT/ARPI alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to findings from the phase 3 PSMAddition trial (NCT04720157).1 These findings were preceded by data demonstrating an improvement in radiographic...
Open in Who Shared Issue with article?

Zin W Myint, MD | Authors | Oncology Nursing News

|
By Zin W. Myint
| Oncology Nursing News Verified
Articles by Zin W Myint, MD With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.
Open in Who Shared Issue with article?
See all 12 articles